This is a preview of subscription content, log in via an institution to check access.
References
Byrne RA, Sarafoff N, Kastrati A, et al. Drug-eluting stents in percutaneous coronary interventions: a benefit-risk assessment. Drug Saf 2009; 32(9):749–70
Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol 2008; 52: 1134–40
Cook S, Ladich E, Nakazawa G, et al. Correlation of intra-vascular ultrasound findings with histopathologic analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation. Epub 2009 Jul 20
Acknowledgements
The Cardiovascular Research Center Aalst has received educational and research support and consulting fees on behalf of Dr Wijns from Abbott Vascular, Biosensors, Biotronik, Cordis Corporation (Johnson & Johnson), Boston Scientific, Devax, Medtronic, Terumo and Xtent. No sources of funding were used to assist in the preparation of this commentary.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wijns, W. First-Generation Drug-Eluting Stents… and Beyond. Drug-Safety 32, 771–773 (2009). https://doi.org/10.2165/11316600-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11316600-000000000-00000